Expanded Newborn Screening: A Chess Board Motif in Public Health

Abstract

Inborn errors of metabolism (IEM) include a large number of genetic disorders caused by lack of functional proteins that result in a blockage of the corresponding metabolic pathway essential for cellular life. IEM are rare or even very rare conditions, whereas with a collective incidence comprised from 1:800 to 1:2,500 live births. Approximately half of all IEM can be treated biochemically, although the success of such treatment is variable. IEM (especially in the neonatal age) may have a rapid evolution to severe and irreversible neurological and mental deficits, coma, and death. Early diagnosis, allowing presymptomatic treatment, can ameliorate prognosis, prevent severe permanent sequelae, and in certain cases avoid death. To ensure accurate diagnosis, effective treatment, and appropriate follow-up, preventive medicine have implemented for IEM screening programs as a powerful tool of secondary prevention. In this respect, expanded newborn screening programs have increased dramatically in the past decade although the number of diseases included in the screening panel varies from state to state. As a consequence, some nations screen for only one or two IEM, some others for several more (up to a few dozen IEM) leading to an inequality of preventive measures in such as delicate fields. Criteria to support and include screening for a specific condition in each country stand from legislation, financial costs prevalence of the disease in that country, availability of treatments, and dedicated funding sources. Currently, lack of sound and complete evidence, as well as different interpretations of the best evidence available, could also be among the factors contributing to the different screening panels across diverse countries worldwide. Within this view, the recommendable approach to assess current newborn screening programs should be based on the methodologies of health technology assessment, taking into account health economics evidence and ethics applied to well-being policies.

Keywords

expanded newborn screening - inborn errors of metabolism - rare diseases - prevention

• References

• 1 Vernon HJ. Inborn errors of metabolism: Advances in diagnosis and therapy. JAMA Pediatr 2015; 169 (8) 778-782
• 2 Sanderson S, Green A, Preece MA, Burton H. The incidence of inherited metabolic disorders in the West Midlands, UK. Arch Dis Child 2006; 91 (11) 896-899
• 3 Polizzi A, Balsamo A, Bal MO, Taruscio D. Rare diseases research and practice. Endocr Dev 2014; 27: 234-256
• 4 Ginocchio VM, Brunetti-Pierri N. Progress toward improved therapies for inborn errors of metabolism. Hum Mol Genet 2015;
• 5 Sparks SE. Update on newborn screening. N C Med J 2013; 74 (6) 514-517
• 6 Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963; 32: 338-343
• 7 Illig R, Torresani T, Sobradillo B. Early detection of neonatal hypothyroidism by serial TSH determination in dried blood. Six months experience with a reliable, efficient and inexpensive method. Helv Paediatr Acta 1977; 32 (4–5) 289-297
• 8 Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 1990; 13 (3) 321-324
• 9 Seashore MR. Tandem spectrometry in newborn screening. Curr Opin Pediatr 1998; 10 (6) 609-614
• 10 la Marca G. Mass spectrometry in clinical chemistry: the case of newborn screening. J Pharm Biomed Anal 2014; 101: 174-182
• 11 McCabe ER, Huang SZ, Seltzer WK, Law ML. DNA microextraction from dried blood spots on filter paper blotters: potential applications to newborn screening. Hum Genet 1987; 75 (3) 213-216
• 12 Dobrowolski SF, Banas RA, Naylor EW, Powdrill T, Thakkar D. DNA microarray technology for neonatal screening. Acta Paediatr Suppl 1999; 88 (432) 61-64
• 13 Caggana M, Jones EA, Shahied SI, Tanksley S, Hermerath CA, Lubin IM. Newborn screening: from Guthrie to whole genome sequencing. Public Health Rep 2013; 128 (Suppl. 02) 14-19
• 14 Lefterova MI, Shen P, Odegaard JI , et al. Next-Generation molecular testing of newborn dried blood spots for Cystic Fibrosis. J Mol Diagn 2016; 18 (2) 267-282
• 15 Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003; 348 (23) 2304-2312
• 16 Marsden D, Levy H. Newborn screening of lysosomal storage disorders. Clin Chem 2010; 56 (7) 1071-1079
• 17 Pollitt RJ, Green A, McCabe CJ , et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997; 1 (7) i-iv , 1–202
• 18 Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 2004; 8 (12) iii , 1–121
• 19 Fischer KE, Rogowski WH. Funding decisions for newborn screening: a comparative review of 22 decision processes in Europe. Int J Environ Res Public Health 2014; 11 (5) 5403-5430
• 20 Fischer KE, Grosse SD, Rogowski WH. The role of health technology assessment in coverage decisions on newborn screening. Int J Technol Assess Health Care 2011; 27 (4) 313-321
• 21 Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR. Newborn screening: toward a uniform screening panel and system. Genet Med 2006; 8 (Suppl. 01) 1S-252S
• 22 Kemper AR, Green NS, Calonge N , et al. Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children. Genet Med 2014; 16 (2) 183-187
• 23 Seymour CA, Thomason MJ, Chalmers RA , et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1997; 1 (11) i-iv , 1–95
• 24 Scaturro G, Sanfilippo C, Piccione M, Piro E, Giuffrè M, Corsello G. Newborn screening of inherited metabolic disorders by tandem mass spectrometry: past, present and future. Pediatr Med Chir 2013; 35 (3) 105-109
• 25 Carbone P, Polizzi A, Sanseverino A, Granata O, Taruscio D and Expanded Newborn Screening Working Group. Newborn screening system for congenital disorders in Italy: a nation-wide analysis. Proceedings from the VIII International Conference on Rare Diseases and Orphan Drugs (ICORD). St. Petersburg (Russia), October 31–November 2, 2013. Rare Dis Orphan Drugs 2014; 1S: 24
• 26 European Commission. Legal basis of EU policy. Council recommendation on action in the field of rare diseases. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF . Accessed April 18, 2016
• 27 Cornel MC, Rigter T, Weinreich SS , et al. A framework to start the debate on neonatal screening policies in the EU: an Expert Opinion Document. Eur J Hum Genet 2014; 22 (1) 12-17
• 28 Loeber JG, Burgard P, Cornel MC , et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis 2012; 35 (4) 603-611
• 29 Burgard P, Rupp K, Lindner M , et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2. From screening laboratory results to treatment, follow-up and quality assurance. J Inherit Metab Dis 2012; 35 (4) 613-625
• 30 Wilson JMG, Jungner G. Principles and Practice of Screening for Diseases. Geneva, Switzerland: World Health Organization, Public Health Papers, No. 34; 1968
• 31 Cerone R, Cassanello M, Caruso U, Schiaffino MC, Lorini R. Neonatal screening for congenital errors of metabolism by means of Tandem Mass: Italian experience [in Italian]. Minerva Pediatr 2007; 59 (5) 488-489
• 32 Blout C, Walsh Vockley C, Gaviglio A, Fox M, Croke B, Williamson Dean L ; Newborn Screening Task Force on behalf of the NSGC Public Policy Committee. Newborn screening: education, consent, and the residual blood spot. The position of the national society of genetic counselors. J Genet Couns 2014; 23 (1) 16-19
• 33 Bavisetty S, Grody WW, Yazdani S. Emergence of pediatric rare diseases: Review of present policies and opportunities for improvement. Rare Dis 2013; 1: e23579
• 34 Wilcken B. Medicine. Newborn screening: gaps in the evidence. Science 2013; 342 (6155) 197-198
• 35 Dhondt JL. Expanded newborn screening: social and ethical issues. J Inherit Metab Dis 2010; 33 (Suppl. 02) S211-S217
• 36 Miller FA, Hayeems RZ, Bombard Y , et al. Public perceptions of the benefits and risks of newborn screening. Pediatrics 2015; 136 (2) e413-e423